[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@BarnyardBull72 David

David posts on X about $lexx, $nvo, $lly, eli lilly the most. They currently have XXX followers and XXX posts still getting attention that total XX engagements in the last XX hours.

Engagements: XX #

• X Week XXX -XX%
• X Month XXXXX -XX%
• X Months XXXXXXX +68,453%

Mentions: X #

• X Week X -XX%
• X Month XX -XX%
• X Months XXX +3,767%

Followers: XXX #

• X Week XXX +0.77%
• X Month XXX +7.40%
• X Months XXX +13,000%

CreatorRank: undefined #

Social Influence #

---

Social category influence stocks

Social topic influence $lexx, $nvo, $lly, eli lilly, categories, $pfe, $mrk, $amgn

Top assets mentioned Novo-Nordisk (NVO) Eli Lilly and Company (LLY) Pfizer, Inc. (PFE) Merck & Co., Inc. (MRK) Amgen, Inc. (AMGN)

Top Social Posts #

---

Top posts by engagements in the last XX hours

"🚨 The Case for a Bidding War Over $LEXX 🚨 DehydraTECH isnt just about semaglutide its a platform that fixes cost tolerability and CNS delivery across multiple blockbuster categories. Heres why the top X global pharmas all have a reason to chase it: $NVO (Novo Nordisk) Needs DehydraTECH to cut API costs eliminate GI side effects and defend its GLP-1 leadership against Lilly. $LLY (Eli Lilly) Cant risk Novo owning the only next-gen oral GLP-1 delivery must counter with its own access. $PFE (Pfizer) Already doubled down on obesity with the $MTSR (Metsera) deal LEXX is the perfect bolt-on to"
X Link @BarnyardBull72 2025-10-04T15:09Z XXX followers, XXX engagements

"$LEXX showed XXX% reduction in nausea for their oral semaglutide interim results 🚨. Human trial readout coming this quarter. $NVO $PFE $LLY $MRK $AMGN"
X Link @BarnyardBull72 2025-10-04T15:39Z XXX followers, XXX engagements